Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges: 2020-2025

Historic Amortization of Deferred Charges for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to $443,000.

  • Mirum Pharmaceuticals' Amortization of Deferred Charges rose 4.48% to $443,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $1.7 million for FY2024, which is 48.70% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $443,000 for Q3 2025, which was up 3.75% from $427,000 recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Amortization of Deferred Charges high stood at $443,000 for Q3 2025, and its period low was -$285,000 during Q4 2021.
  • Its 3-year average for Amortization of Deferred Charges is $408,100, with a median of $415,000 in 2024.
  • In the last 5 years, Mirum Pharmaceuticals' Amortization of Deferred Charges plummeted by 456.25% in 2021 and then skyrocketed by 32.57% in 2024.
  • Mirum Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at -$285,000 in 2021, then reached $399,000 in 2023, then increased by 4.26% to $416,000 in 2024, then climbed by 4.48% to $443,000 in 2025.
  • Its Amortization of Deferred Charges stands at $443,000 for Q3 2025, versus $427,000 for Q2 2025 and $433,000 for Q1 2025.